Healthy females or males aged between 18 and 60 years old, those who are positive in the lactic acid stinging test, with sensitive, reddish and dry facial skin, and the ITA° value of the normal facial skin being between 28° and 41°. The tested area has been diagnosed by a clinical doctor as melasma or seborrheic keratosis, and there is at least one part where the difference in ITA° value from the
Conditions
Interventions
Experimental group:The subjects in this group were provided with the test product and instructed to use it as directed (Arbutin Radiant Brightening Micro Serum).
Sponsors
Dematology Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Healthy female or male subjects aged 18–60 years; 2. Positive result in the lactic acid stinging test; 3. Facial skin exhibiting sensitivity, redness, and dryness; 4. ITA° value of normal facial skin tone ranging between 28° and 41°; 5. No history of allergic diseases or allergies to cosmetics or other topical agents; 6. No history of photosensitivity disorders; no use of photosensitizing medications in the recent period; 7. Target area clinically diagnosed by a physician as melasma or seborrheic keratosis, with at least one lesion exhibiting an ITA° difference greater than 10° compared to adjacent surrounding skin and a diameter of at least 3 mm; 8. Good compliance with the study protocol and strong communication ability; 9. Willingness to participate in follow-up visits and undergo relevant non-invasive assessments; 10. Capable of understanding the study procedures, voluntarily participating in the trial, and providing written informed consent.
Exclusion criteria
Exclusion criteria: 1. Individuals with a history of skin diseases such as psoriasis, eczema, atopic dermatitis, or severe acne, or those with other chronic systemic diseases; 2. Individuals who have taken or applied corticosteroids or other anti-inflammatory medications orally or topically within the past 1 month; 3. Individuals who have used glycolic acid, salicylic acid, or any other products or medications that may affect skin pigmentation (e.g., hydroquinone-based formulations) within the past 2 months; 4. Individuals who have applied retinoid-based formulations to the test area or undergone cosmetic procedures such as chemical peels, laser therapy, or intense pulsed light (IPL) treatments within the past 3 months; 5. Individuals who cannot avoid prolonged sun exposure; 6. Individuals who have participated in other clinical trials within the past 2 months; 7. Women who are planning pregnancy, currently pregnant, or breastfeeding; 8. Individuals with obvious scars, pigmentation, skin atrophy, port-wine stains, sunspots, wounds, excessive hair, abrasions, tattoos, or other skin imperfections in or near the test area that may interfere with evaluation of results; 9. Individuals with highly sensitive constitutions or known allergies to cosmetic ingredients, daily chemical products, alcohol, rubber, or medications; 10. Individuals with other medical conditions that may affect trial outcomes (e.g., coagulation disorders, severe hyperglycemia, hypertension, hyperlipidemia, psychiatric disorders, or other significant medical histories); 11. Individuals deemed unsuitable for participation in the trial based on clinical assessment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The content of melanin in the skin; | — |
Secondary
| Measure | Time frame |
|---|---|
| Transepidermal water loss;Clinical assessment questionnaire;The water content of the stratum corneum of the skin;VISIA CR spot analysis;Skin colorimetric ITA° value;Research participant self - assessment questionnaire;Lactic acid stinging test; | — |
Countries
China
Contacts
Public ContactYe Li
Dematology Hospital of Southern Medical University
Outcome results
None listed